A Dose Escalation Study to Evaluate the Effect of RT234 in Subjects With Pulmonary Arterial Hypertension

NCT05343637 | Completed Phase 2 FDA Drug FDA Device

• 2 other identifiers: RT234-CL201ACTRN12619001178134
• Study Type: interventional
• Target: 14
• Locations: 1 country
• Sites: 3

Brief Summary

This multicenter, open label, Phase 2a study is designed to evaluate the effect of inhaled RT234 delivered in a dose escalation manner on the change in pulmonary vascular resistance (PVR) in subjects with Pulmonary Arterial Hypertension (PAH) undergoing Right heart catheterization (RHC). This study is also known as Vardenafil Inhaled for Pulmonary Arterial Hypertension PRN Phase 2a (VIPAH-PRN 2a) study

Conditions

Pulmonary Arterial Hypertension

Keywords

Pulmonary Arterial Hypertension; Familial Primary Pulmonary Hypertension; Vascular Diseases; Cardiovascular Diseases; Hypertension, Pulmonary; Lung Diseases; Respiratory Tract Diseases; Vardenafil Dihydrochloride; Vasodilator Agents; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action

Outcome Measures

Primary Outcomes (6)

• Evaluation of adverse events (AEs)

  Evaluation of AEs will be measured by clinical examination and participant self-reporting. Known or possible adverse events include headache, lightheadedness and cough.

  Screening to Day 30

• Peak plasma concentration (Cmax)

  Change in Cmax at each dose level on Day 1.

  At baseline, 5, 15, 30, 45 and 60 minutes post-end of inhalation for the first RT234 dose and at 5, 15, 30, 45, 60, 75, 90, 105 and 120 minutes post-end of inhalation for the second RT234 dose.

• Time to peak plasma concentration (Tmax)

  Change in Tmax at each dose level on Day 1.

  At baseline, 5, 15, 30, 45 and 60 minutes post-end of inhalation for the first RT234 dose and at 5, 15, 30, 45, 60, 75, 90, 105 and 120 minutes post-end of inhalation for the second RT234 dose.

• Area under the plasma concentration versus time curve (AUC)

  Change in AUC at each dose level on Day 1.

  At baseline, 5, 15, 30, 45 and 60 minutes post-end of inhalation for the first RT234 dose and at 5, 15, 30, 45, 60, 75, 90, 105 and 120 minutes post-end of inhalation for the second RT234 dose.

• Terminal half-life

  Change in terminal half-life at each dose level on Day 1.

  At baseline, 5, 15, 30, 45 and 60 minutes post-end of inhalation for the first RT234 dose and at 5, 15, 30, 45, 60, 75, 90, 105 and 120 minutes post-end of inhalation for the second RT234 dose.

• Change in pulmonary vascular resistance (PVR)

  Maximal change from baseline in PVR assessed at the time by right heart catheterisation (RHC).

  At baseline, 5, 15, 30, 45 and 60 minutes post-end of inhalation for the first RT234 dose and at 5, 15, 30, 45, 60, 75, 90, 105 and 120 minutes post-end of inhalation for the second RT234 dose on Day 1.

Study Arms (3)

RT234 - Cohort 1

EXPERIMENTAL

Participants will receive RT234 as 0.2 mg and 0.6 mg

Combination Product: Drug: RT234 - vardenafil inhalation powder; Device: RS01 dry powder inhaler (RS01 DPI)

RT234 - Cohort 2

EXPERIMENTAL

Participants will receive RT234 as 0.6 mg and 1.2 mg

Combination Product: Drug: RT234 - vardenafil inhalation powder; Device: RS01 dry powder inhaler (RS01 DPI)

RT234 - Cohort 3

EXPERIMENTAL

Participants will receive RT234 as 1.2 mg and 2.4 mg

Combination Product: Drug: RT234 - vardenafil inhalation powder; Device: RS01 dry powder inhaler (RS01 DPI)

Interventions

Drug: RT234 - vardenafil inhalation powder; Device: RS01 dry powder inhaler (RS01 DPI) COMBINATION_PRODUCT

RT234 is a drug/device combination product composed of vardenafil hydrochloride as the drug constituent and will utilize RS01 DPI device.

Also known as: vardenafil inhalation powder, inhaled vardenafil

RT234 - Cohort 1; RT234 - Cohort 2; RT234 - Cohort 3

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Between 18 and 80 years of age, inclusive.
• Diagnosis of RHC-confirmed WHO Group 1 PAH in any of the following three categories: Idiopathic, primary or familial pulmonary arterial hypertension (IPAH, PPH, or FPAH); OR PAH associated with one of the following connective tissue diseases (CTD):
• Systemic sclerosis (scleroderma)
• Limited scleroderma
• Mixed connective tissue disease
• Systemic lupus erythematosus
• Overlap syndrome
• Other autoimmune disorders;
• OR PAH associated with:
• Human immunodeficiency virus (HIV) infection with no evidence of opportunistic infection in the preceding 6 months;
• Simple, congenital systemic-to-pulmonary shunts at least one-year post-surgical repair.
• Exposure to legal drugs, chemicals and toxins, such as fenfluramine, derivatives, other anorexigens, toxic rapeseed oil or L-tryptophan. Subjects with PAH associated with illegal drug use, such as methamphetamine, were excluded.
• Previous diagnosis with PAH with the following conditions:
• Stable PAH without significant adjustments of disease-specific background PAH therapy, at least 3 months prior to RHC procedure;
• If on corticosteroids, has been receiving a stable dose of ≤ 20 mg/day of prednisone (or equivalent dose of other corticosteroid) for at least 30 days prior to RHC procedure.

You may not qualify if:

• Baseline systemic hypotension, defined as MAP \< 50 mmHg or systolic blood pressure (SBP)\< 90 mmHg at Screening.
• Requirement of intravenous inotropes within 30 days prior to RHC procedure.
• Use of oral, topical or inhaled nitrates within 14 days prior to RHC procedure.
• Uncontrolled systemic hypertension: SBP \> 160 mmHg or diastolic blood pressure (DBP) \>100 mmHg at Screening.
• History of portal hypertension or chronic liver disease, including active viral replication of hepatitis B and/or hepatitis C or classified as having moderate to severe hepatic impairment (Child-Pugh Class B-C).
• Chronic renal insufficiency as defined by serum creatinine \> 2.5 mg/dL at Screening or requires dialysis.
• History of atrial septostomy.
• Unrepaired congenital heart disease (CHD).
• Pericardial constriction; restrictive or congestive cardiomyopathy.
• History of left ventricular ejection fraction (EF) \< 40% by multiple gated acquisition scan (MUGA), angiography, echocardiography, or cardiac magnetic resonance imaging (CMRI).
• Symptomatic coronary disease with demonstrable ischemia.
• Poorly controlled asthma defined by active wheezing and/or cough at the time of Screening or day of participation in Parts A and B.
• Clinically significant intercurrent illness (including lower respiratory tract infection) or clinically significant surgery within 30 days prior to study drug administration.
• Clinical RHC \< 14 days prior to Screening.
• History of non-arteritic anterior ischemic optic neuropathy (NAION) or retinitis pigmentosa.

Sponsors & Collaborators

• Respira Therapeutics, Inc.: lead

Study Sites (3)

St Vincent's Hospital

Darlinghurst, New South Wales, 2010, Australia

Location

Royal Hobart Hospital

Hobart, Tasmania, 7000, Australia

Location

The Alfred Hospital

Melbourne, Victoria, 3004, Australia

Location

MeSH Terms

Conditions

Pulmonary Arterial Hypertension; Familial Primary Pulmonary Hypertension; Vascular Diseases; Cardiovascular Diseases; Hypertension, Pulmonary; Lung Diseases; Respiratory Tract Diseases

Condition Hierarchy (Ancestors)

Hypertension

Study Officials

• Carol Ann Satler, MD, PhD

  Respira Therapeutics

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 4, 2022
• First Posted: April 25, 2022
• Study Start: July 30, 2019
• Primary Completion: January 17, 2020
• Study Completion: January 17, 2020
• Last Updated: April 25, 2022

Record last verified: 2022-04

Data Sharing

• IPD Sharing: Will not share

Locations

AU (3)